Novoheart to Co-develop First of its Kind Human Heart-in-a-Jar Model of Heart Failure with AstraZene – PharmiWeb.com
By daniellenierenberg
HONG KONG, Nov. 26, 2019 /PRNewswire/ --Novoheart("Novoheart" or the "Company") (TSXV: NVH; FWB: 3NH), a global stem cell biotechnology company, is pleased to announce a collaboration with global biopharmaceutical company AstraZeneca, in an effort to develop the world's first human-specific in vitro, functional model of heart failure with preserved ejection fraction (HFpEF), a common condition especially among the elderly and in women, with the reported prevalence approaching 10% in women over the age of 80 years.[1]
Heart failure (HF) is a global pandemic with an estimated 64.3 million cases worldwide in 2017, with an increasing trend in prevalence[2]. The annual global economic burden of HF is estimated at over US$100 billion[3]. Accounting for approximately 50% of HF cases, HFpEF in particular is a major and growing public health problem worldwide, with its pathological mechanisms and diverse etiology poorly understood. Due to these complexities, models of the disease available to date, including various animal models, have limited ability to mimic the clinical presentation of HFpEF[4]. Therefore, drug developers lack an effective tool for preclinical testing of drug candidates for efficacy, and as a result, clinical outcomes for HFpEF have not improved over the last decades, with no effective therapies available.
In collaboration with the Cardiovascular, Renal and Metabolism therapy area of AstraZeneca, the initial phase of the project aims to establish a new in vitro model, leveraging Novoheart's proprietary 3-D human ventricular cardiac organoid chamber (hvCOC) technology, that reproduces key phenotypic characteristics of HFpEF. Also known as "human heart-in-a-jar", the hvCOC is the only human engineered heart tissue available on the market to date that enables clinically informative assessment of human cardiac pump performance including ejection fraction and developed pressure. Unlike animal models, engineered hvCOCs can be fabricated with specific cellular and matrix compositions, and patient-specific human induced pluripotent stem cells (iPSCs), that allow control over their physical and mechanical properties to mimic those observed in HFpEF patient hearts. Together with Novoheart's proprietary hardware and software, this aims to provide a unique assay for understanding the mechanisms of HFpEF, identification of new therapeutic targets, and assessment of novel therapeutics for treating HFpEF patients. Novoheart will exclusively own the intellectual property rights to the newly developed HFpEF hvCOC model.
"We are delighted to partner with AstraZeneca, an organization which has long invested in cardiovascular research and is committed to bringing new therapeutic solutions to patients with heart failure," said Novoheart CSO, Dr. Kevin Costa. "We look forward to co-developing this new HFpEF hvCOC model into a powerful new tool in the worldwide battle against heart failure."
Regina Fritsche Danielson, Senior Vice President, Head of Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, said, "There are significant unmet treatment needs in patients with heart failure with preserved ejection fraction. By combining Novoheart's proprietary hvCOC model with our expertise in heart failure, we aim to create the first in vitro model reproducing phenotypic characteristics of heart failure with preserved ejection fraction. This could bridge the gap between in vivo animal models and clinical trials to help accelerate the drug discovery process by providing human-specific preclinical data."
[1] Heart Fail Clin. 2014; 10(3):377-388.
[2] Lancet. 2018; 392:1789-1858.
[3] Int J Cardiol. 2014; 171(3):368-76.
[4]JACC Basic Transl Sci. 2017; 2(6):770-789.
About Novoheart:
Novoheartis a global stem cell biotechnology company pioneering an array of next-generation human heart tissue prototypes. It is the first company in the world to have engineered miniature living human heart pumps that can revolutionize drug discovery, helping to save time and money for developing new therapeutics. Also known as 'human heart-in-a-jar', Novoheart's bio-artificial human heart constructs are created using state-of-the-art and proprietary stem cell and bioengineering approaches and are utilized by drug developers for accurate preclinical testing of the effectiveness and safety of new drugs, maximizing the successes in drug discovery whilst minimizing costs and harm caused to patients. With the recent acquisition of Xellera Therapeutics Limited for manufacturing Good Manufacturing Product (GMP)-grade clinical materials, Novoheart is now developing gene- and cell-based therapies as well as next-generation therapeutics for cardiac repair or regeneration.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as "anticipate", "believe", "plan", "estimate", "expect", and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the risks identified in under the heading "Risk Factors" in Novoheart's annual information form for the year ended June 30, 2018 or other reports and filings with the TSX Venture Exchange and applicable Canadian securities regulators. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and the respective companies undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements.
Logo - https://photos.prnasia.com/prnh/20191126/2654235-1LOGO
SOURCE Novoheart
Read more from the original source:
Novoheart to Co-develop First of its Kind Human Heart-in-a-Jar Model of Heart Failure with AstraZene - PharmiWeb.com
- Meditation increases blood flow in the heart, PET scans show - Health Imaging - December 8th, 2019
- With another $26M, Japan's Heartseed aims to advance iPSC-derived regenerative medicine for heart failure - BioWorld Online - December 8th, 2019
- CALQUENCE Significantly Prolonged the Time Patients Lived Without Disease Progression or Death in Previously Untreated Chronic Lymphocytic Leukemia -... - December 8th, 2019
- PHATED to be: Yale researchers give shape to big data - Yale News - December 6th, 2019
- Spinning Disk Confocal Microscope Market Growth Fueled by Reviving Techniques to Treat Heart Failure with Cardiac Regenerative Medicine - MENAFN.COM - December 6th, 2019
- Stem Cell Therapy Market Robust pace of Industry during 2017-2025 - News Description - December 6th, 2019
- Year in Review: Respiratory Infection - MedPage Today - December 6th, 2019
- MarketsandMarkets - 4th Annual Bioprocessing of Advanced Cellular Therapies & Regenerative Medicine Congress - Hitz Dairies - December 6th, 2019
- Global Synthetic Stem Cells Market :Industry Analysis and Forecast (2018-2026) - The Market Expedition - December 3rd, 2019
- Professor Recognized For Cardiac Regeneration Research - WPI News - December 3rd, 2019
- Stem cells may trigger immune repair to mend hearts - BioNews - December 2nd, 2019
- Stem cells do help restore heart function but in a different way - News-Medical.net - November 29th, 2019
- Can intermittent fasting help you live long? - Times of India - November 29th, 2019
- Novoheart to Co-develop First of its Kind Human Heart-in-a-Jar Model of Heart Failure with AstraZeneca - GlobeNewswire - November 29th, 2019
- Toddler Bravely Cheats Death After He Survived Rare Cancer And Its Treatment - The Digital Weekly - November 29th, 2019
- South Carolina toddler survives rare cancer and the risky procedure used to treat it - USA TODAY - November 28th, 2019
- Stem cells don't repair injured hearts, but inflammation might, study finds - FierceBiotech - November 28th, 2019
- Stem Cell Therapy May Improve Heart Health In New Ways - TheHealthMania - November 28th, 2019
- 'My daughter's death took me to the darkest place, but I've learned it's possible to come back' - Telegraph.co.uk - November 28th, 2019
- Stem Cell Assay Market Demand with Leading Key Players and New Investment Opportunities Emerge To Augment Segments in Sector By 2025 - The Denton... - November 28th, 2019
- Activation of the Immune System Underlies Cardiac Cell Therapies - The Scientist - November 27th, 2019
- Cell Separation Technology Market Size Projected to Rise Lucratively During 2019 2027 - News Description - November 27th, 2019
- Merck's KEYTRUDA (pembrolizumab) Now Approved in China for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) in... - November 26th, 2019
- Trump is blocking vital biomedical research - CNN - November 26th, 2019
- Stem Cell Therapy Market Segmentation, Assessment and Growth Opportunities by Forecast 2025 - Tech Admirers - November 26th, 2019
- Stem Cells For Heart Health: What The Current Research ... - November 25th, 2019
- Cardiol Therapeutics Announces Clinical Steering Committee for Phase 2 International Trial in Acute Myocarditis Using CardiolRx(TM) 100 | INN -... - November 25th, 2019
- Biobots are hybrid machines that have muscles and nerves - DesignNews - November 23rd, 2019
- CALQUENCE Approved in the US for Adult Patients With Chronic Lymphocytic Leukemia - Business Wire - November 23rd, 2019
- Suspended animation induced in humans for the first time - CNET - November 22nd, 2019
- AbbVie to Present Latest Clinical Research in the Treatment of Leukemias, Lymphomas and Other Blood Cancers at 2019 ASH Annual Meeting - P&T Community - November 22nd, 2019
- Cell Separation Technology Market Growth Forecast through 2019-2027 with Upcoming Trends and Market Opportunities - Montana Ledger - November 22nd, 2019
- CALQUENCE Approved in the US for Adult Patients With Chronic Lymphocytic Leukemia - BioSpace - November 22nd, 2019
- Cell Separation Technology Market is Expected To Elevate To a Stellar Value of US$ 2.7 Bn by 2027 - Downey Magazine - November 22nd, 2019
- Breaking News: Cardiol Therapeutics Announces Clinical Steering Committee for Phase 2 International Trial in Acute Myocarditis Using CardiolRx(TM) 100... - November 20th, 2019
- Stem Cell Therapy Market to Surge at a Robust Pace in Terms of Revenue Over 2025 - The Denton Chronicle - November 20th, 2019
- European Commission Approves Two New Regimens of Merck's KEYTRUDA (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent... - November 20th, 2019
- Validea's Top Five Healthcare Stocks Based On Motley Fool - 11/17/2019 - Nasdaq - November 18th, 2019
- Human heart cells behave differently in space - SellRegular - November 18th, 2019
- New cell therapy improves memory and stops seizures following TBI: Study - ANI News - November 17th, 2019
- Celgene Receives CHMP Positive Opinion for REVLIMID (lenalidomide) in Combination With Rituximab for the Treatment of Adult Patients With Previously... - November 15th, 2019
- The Heart of the Matter: Leveraging Advances in Cardiac Biology to Innovate Gene-Based Therapies for Heart Failure - Physician's Weekly - November 14th, 2019
- Human Heart Cells Transform in Space; Return to Normal on Earth: Study - The Weather Channel - November 14th, 2019
- Human Heart Cells Alter In Spaceflight But Return To Normal Quickly On Earth - Pragativadi - November 12th, 2019
- Financial Contrast: BioRestorative Therapies (OTCMKTS:BRTX) and Livongo Health (OTCMKTS:LVGO) - DFS Caller - November 12th, 2019
- Stem Cell Therapy Market Poised to Expand at a Robust Pace Over 2025 - Tech Admirers - November 11th, 2019
- Dystrogen Therapeutics Announces That Treatment With DEC Cells Improves Cardiac Function Cardiology2.0 - Cardiology2.0 - November 11th, 2019
- Reviewing US Stem Cell (OTCMKTS:USRM) and Auxly Cannabis Group (OTCMKTS:CBWTF) - Riverton Roll - November 11th, 2019
- Going into Space Changes the Human Heart Cells, but What Happens When They Get Back on Earth? - Henri Le Chat Noir - November 10th, 2019
- Dr Eilish McLoughlin honoured by SFI for Outstanding Contribution to STEM Communication - Dublin City University - November 9th, 2019
- Space travel affects heart cells, but only temporarily - BBC Focus Magazine - November 9th, 2019
- Teva and Celltrion Announce the Availability of TRUXIMA (rituximab-abbs) Injection, the First Biosimilar to Rituxan (rituximab) in the United States -... - November 8th, 2019
- Takeda to Highlight Expanded Portfolio of Products Across Oncology and Hematology at 61st American Society of Hematology (ASH) Annual Meeting -... - November 8th, 2019
- bluebird bio to Present New Data from Gene and Cell Therapy Programs at 61st American Society of Hematology Annual Meeting and Exposition - Financial... - November 6th, 2019
- Reviewing Capricor Therapeutics Inc. (CAPR)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - FinanceMercury - November 6th, 2019
- Dystrogen Therapeutics Announces That Treatment With Dystrophin Expressing Chimeric (DEC) Cells Improves Cardiac Function in Preclinical Duchenne's... - November 5th, 2019
- Future Outlook: Autologous Stem Cell Based Therapies Market Prediction and Analysis Offered By New Study 2019 2025: Leading Key Players: JCR... - November 5th, 2019
- Head-To-Head Analysis: BioRestorative Therapies (OTCMKTS:BRTX) versus Livongo Health (OTCMKTS:LVGO) - Casper Courier - November 5th, 2019
- Latest Released Report on Autologous Stem Cell Based Therapies Market to Witness the Highest Growth Globally in Coming Years: Osiris... - November 3rd, 2019
- InGeneron Announces Publication of Preclinical Results for its Cell Therapy in Chronic Ischemic Heart Failure - Business Wire - November 1st, 2019
- The Stars in Our Brains - Duke Department of Neurology - October 30th, 2019
- Global Cell Based Assay & High Content Screening Markets, 2020-2024 | Forecast by Application with Executive & Consultant Guides -... - October 30th, 2019
- Michael Schumacher: Has the racing champ recovered? Stem Cell Therapy doctor unknowingly confirmed Schumi's procedure? - EconoTimes - October 28th, 2019
- Regenerative Medicine Market Industry Outlook, Growth Prospects and Key Opportunities - Health News Office - October 25th, 2019
- Plant of the week: Plant thought to boost milk production now used for skin eruptions - Cyprus Mail - October 25th, 2019
- BioRestorative Therapies Receives A Second Patent in Australia For Its Metabolic Program - Yahoo Finance - October 23rd, 2019
- Bayer Announces Recipients of the Pulmonary Hypertension Accelerated Bayer (PHAB) Awards at CHEST Annual Meeting 2019 - PRNewswire - October 22nd, 2019
- Hemostemix Announces Positive Results and Conclusions Reported in Phase II CLI Trial Abstract - Yahoo Finance - October 22nd, 2019
- Hemostemix Announces Positive Results and Conclusions Reported in Phase II CLI Trial Abstract - GlobeNewswire - October 21st, 2019
- Best Growth Report On Autologous Stem Cell Based Therapies Market Survey 2019 Industry Outlines, Future Trends, Forecasts And Regional Segmented... - October 21st, 2019
- Bayer Announces Recipients of the Pulmonary Hypertension Accelerated Bayer (PHAB) Awards at CHEST Annual Meeting 2019 - BioSpace - October 21st, 2019
- Drug Treats Inflammation Related to Genetic Heart Disease - Technology Networks - October 18th, 2019
- Analysis on Worldwide Autologous Stem Cell Based Therapies Market Inclinations Exhibit Growing Demand During The Period Until 2025 - Wheel Chronicle - October 18th, 2019
- Sphingosine 1-phosphate: Lipid signaling in pathology and therapy - Science Magazine - October 18th, 2019
- Research Roundup: Genomic Dark Matter Mutation and More - BioSpace - October 18th, 2019
- SIDS May Be Linked To A Genetic Inability To Digest Milk, Study Finds - Moms - October 18th, 2019
- Merck Receives Positive EU CHMP Opinion for Two New Regimens of KEYTRUDA (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable... - October 18th, 2019
- 6 Bodily Tissues That Can Be Regenerated Through Nutrition - The Epoch Times - October 18th, 2019
- Reviewing Cellular Biomedicine Group Inc. (CBMG)'s and VistaGen Therapeutics Inc. (NASDAQ:VTGN)'s results - MS Wkly - October 18th, 2019
- Some cases of SIDS may have this genetic cause - Futurity: Research News - October 15th, 2019
